BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05089084 (ARO-APOC3 in Familial Chylomicronemia): BVCT ex-ante prediction vs. reported outcome

On 14 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 3 Jun 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05089084
Acronym
PALISADE
Drug Name
ARO-APOC3
Drug MoA
siRNA-GalNAc conjugate that suppresses APOC3 mRNA
Drug Modality
small interfering RNA (siRNA) antisense oligonucleotide
Drug Class
First-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Familial Chylomicronemia
Human Patients
75
Sponsor
Arrowhead Pharmaceuticals
Phase
Phase 3

Prediction of , index 793

Prospective Prediction
Prediction Index
793
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
110 days in advance
Readout Data Interpretation
80% triglyceride reduction; 94% APOC3 reduction.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Phase
Phase 3
Status
Completed
Enrollment
75
Lead sponsor
Arrowhead Pharmaceuticals
Conditions
Familial Chylomicronemia
Interventions
DRUG: Plozasiran; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2021-12-14
Primary completion
2024-04-29
Completion
2026-04-21
Results first posted
2026-02-04
Primary outcomes
  • Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10)

NCT05089084 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials